New cell therapy takes on Hard-to-Treat myeloma
NCT ID NCT07100067
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new cell therapy called LCAR-F33S in 35 people with multiple myeloma that has come back or stopped responding to other treatments. The therapy uses a patient's own immune cells, which are modified in a lab to attack the cancer. The main goals are to check safety, find the right dose, and see if it shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LCAR-F33S cells (a type of CAR T-cell therapy made from the patient's own immune cells)
- What this could lead to
- If it works, this could offer a new treatment option for people with multiple myeloma that has stopped responding to standard therapies.
- What could go wrong
- This is a very early, small study (35 people) focused on safety and dosing. The treatment may not work, and there are risks of serious side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Boren Hospital
NOT_YET_RECRUITINGBeijing, China
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, China
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, China
-
Wuhan Union Hospital
RECRUITINGWuhan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.